Review Article
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Table 4
Selected clinical
trials of panitumumab. mCRC, metastatic
colorectal cancer; BSC, best supportive care; OS, overall survival; PFS, progression free survival; ORR, overall response rate; SD, stable disease; FOLFOX, 5 Flourouracil/Folinic Acid and oxaliplatin; FOLFIRI, 5 Flourouracil/Folinic Acid and Irinotecan.
| | Malignancy | Regimen | Number of patients | Results | Comments |
| | mCRC | Panitumumab vs. BSC
[35] | 463 pts
Pts with progression after
standard chemotherapy | Panitumumab: ORR (10%)
PFS (13.8 weeks) BSC:
ORR (0%) PFS (8.5 weeks) | No significant improvement in
OS |
| | mCRC | Panitumumab monotherapy after
disease progression with BSC
[36] | 176 pts
Pts with progression of
disease in BSC arm of Panitumumab vs. BSC trial [35] | Panitumumab: ORR (11.6%)
SD (33%) Median PFS of 9.4 weeks | Results comparable to initial
study |
| | mCRC | FOLFOX or FOLFIRI with
Bevacizumab +/ Panitumumab
[37] | 823 pts | FOLFOX, Bevacizumab,
Panitumumab:
Median PFS (9.5 mo) OS (19.3 mo)
FOLFOX, Bevacizumab: Median PFS (11 mo)
OS (20.6 mo) | Panitumumab in combination
with FOLFOX and bevacizumab was associated with a shorter PFS and increased
toxicity |
|
|
